Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Morillas, C. (Carlos) | - |
dc.creator | Escalada, J. (Javier) | - |
dc.creator | Palomares, R. (Rafael) | - |
dc.creator | Bellido, D. (Diego) | - |
dc.creator | Gómez-Peralta, F. (F.) | - |
dc.creator | Pérez, A. (Antonio) | - |
dc.date.accessioned | 2022-03-22T08:24:04Z | - |
dc.date.available | 2022-03-22T08:24:04Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Morillas, C. (Carlos); Escalada, J. (Javier); Palomares, R. (Rafael); et al. "Treatment of type 2 diabetes by patient profile in the clinical practice of endocrinology in Spain: Delphi study results from the think twice program". Diabetes Therapy. 10, 2019, 1893 - 1907 | es |
dc.identifier.issn | 1869-6961 | - |
dc.identifier.uri | https://hdl.handle.net/10171/63278 | - |
dc.description.abstract | Introduction: The aim of this Delphi study is to unveil the management of patients with type 2 diabetes (T2D) and different levels of complexity in the clinical practice in Spain. Methods: Based on the common management practices of T2D profiles reported by Spanish endocrinologists, a Delphi questionnaire of 55 statements was developed and responded to by a national panel (n = 101). Results: A consensus was reached for 30 of the 55 statements. Regarding overweight patients inadequately controlled with metformin, treatment with a sodium-glucose transport protein 2 inhibitor (SGLT2-I) is preferred over treatment with a dipeptidyl peptidase-4 inhibitor (DPP4-I). If the patient is already being treated with a DPP4-I, an SGLT2-I is added on to the treatment regimen rather than replacing the DPP4-I. Conversely, if the treatment regimen includes a sulfonylurea, it is usually replaced by other antihyperglycemic agents. Current treatment trends in uncontrolled obese patients include the addition of an SGLT2-I or a glucagon-like peptide-1 receptor agonist (GLP1-RA) to background therapy. When the glycated hemoglobin target is not reached, triple therapy with metformin ? GLP1-RA ? SGLT2-I is initiated. Although SGLT2-Is are the treatment of choice in patients with T2D and heart failure or uncontrolled hypertension, no consensus was reached regarding the preferential use of SGLT2- Is or GLP1-RAs in patients with established cardiovascular disease. Conclusion: Consensus has been reached for a variety of statements regarding the management of several T2D profiles. Achieving a more homogeneous management of complex patients with T2D may require further evidence and a better understanding of the key drivers for treatment choice. | es_ES |
dc.description.sponsorship | Logistic support was provided by ESTEVE Pharmaceuticals S.A Spain. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Springer Science and Business Media LLC | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Clinical practice | es_ES |
dc.subject | Complex patient | es_ES |
dc.subject | Delphi questionnaire | es_ES |
dc.subject | Endocrinology | es_ES |
dc.subject | Type 2 diabetes | es_ES |
dc.title | Treatment of type 2 diabetes by patient profile in the clinical practice of endocrinology in Spain: Delphi study results from the think twice program | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.description.note | This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/ by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. | es_ES |
dc.identifier.doi | 10.1007/s13300-019-0671-x | - |
dadun.citation.endingPage | 1907 | es_ES |
dadun.citation.publicationName | Diabetes Therapy | es_ES |
dadun.citation.startingPage | 1893 | es_ES |
dadun.citation.volume | 10 | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.